Abstract
The ability of small nucleic acids to modulate gene expression via a range of processes has been widely explored. Compared with conventional treatments, small nucleic acid therapeutics have the potential to achieve long-lasting or even curative effects via gene editing. As a result of recent technological advances, efficient small nucleic acid delivery for therapeutic and biomedical applications has been achieved, accelerating their clinical translation. Here, we review the increasing number of small nucleic acid therapeutic classes and the most common chemical modifications and delivery platforms. We also discuss the key advances in the design, development and therapeutic application of each delivery platform. Furthermore, this review presents comprehensive profiles of currently approved small nucleic acid drugs, including 11 antisense oligonucleotides (ASOs), 2 aptamers and 6 siRNA drugs, summarizing their modifications, disease-specific mechanisms of action and delivery strategies. Other candidates whose clinical trial status has been recorded and updated are also discussed. We also consider strategic issues such as important safety considerations, novel vectors and hurdles for translating academic breakthroughs to the clinic. Small nucleic acid therapeutics have produced favorable results in clinical trials and have the potential to address previously "undruggable" targets, suggesting that they could be useful for guiding the development of additional clinical candidates.
Introduction: Targeting the "Undruggable"
Traditional small-molecule and protein-based drugs are inherently limited by their target scope; they can only interact with proteins. However, protein-coding sequences represent only about 1.5% of the human genome, and an estimated 80% of those proteins are considered "undruggable" by conventional means. Small nucleic acid therapeutics (SNATs) bypass this limitation by targeting the genetic blueprints themselves—mRNA or DNA. While the theoretical potential of SNATs has been recognized for decades, their practical application faced three primary hurdles: rapid enzymatic degradation (stability), immune system recognition (immunogenicity), and the difficulty of crossing cellular membranes (delivery).
The Development Pipeline: From Bench to Clinic
The transition of SNATs from laboratory curiosities to approved medicines requires a sophisticated, multi-platform approach. This pipeline integrates computational design, chemical engineering, and advanced delivery systems to ensure that therapeutic sequences are both potent and safe.
The laboratory phase relies on several key pillars:
- Design Platform: Utilizing AI and machine learning (e.g., AttSiOff, AGILE) to predict silencing activity and minimize off-target effects.
- Modification Platform: Engineering the ribose sugar (2'-OMe, 2'-MOE), phosphate backbone (phosphorothioate), and nucleobases to enhance stability.
- Delivery Platform: Developing non-viral vectors such as Lipid Nanoparticles (LNPs) and the "gold standard" for liver targeting, GalNAc conjugates.
Clinical Translation and Milestones
The field has reached a tipping point, with 19 small nucleic acid drugs currently on the market as of late 2024. This success is the result of decades of foundational research finally translating into a surge of clinical trials and regulatory approvals.
Key successes include drugs like Nusinersen, which has fundamentally changed the prognosis for Spinal Muscular Atrophy (SMA), and Inclisiran, a cholesterol-lowering siRNA that requires only a single subcutaneous injection every six months. The development of GalNAc conjugates has been particularly revolutionary, increasing hepatocyte-targeted delivery efficiency by 6–7 fold compared to unconjugated versions.
Key Technological Advances
- The "Gapmer" Strategy: Modern ASOs often use a DNA center flanked by modified RNA to recruit RNase H1, which physically slices target mRNA for more potent silencing.
- The GalNAc Revolution: By tethering a specific sugar to the drug, researchers have created a "GPS" that binds specifically to receptors on liver cells, making liver-related disorders the primary success story of genetic medicine.
- AI-Driven Discovery: The shift toward in silico screening allows researchers to evaluate thousands of sequences for potency and safety before synthesis, significantly accelerating the R&D timeline.
Limitations and Future Outlook
Despite significant progress, challenges remain. The "liver trap" is a major bottleneck; while targeting the liver is now highly efficient, reaching the brain, heart, or tumors remains difficult. Additionally, certain chemical modifications can still trigger toxicity, and the high cost of these "boutique" medicines limits global accessibility. Future research is directed toward extrahepatic delivery—using peptides or exosomes to reach other organs—and the integration of AI to create "smart" nucleic acids that only activate under specific cellular conditions.
Summary updated